冠心病合并血小板减少的分析与处理策略  

Analysis and management of coronary heart disease complicated by thrombocytopenia

作　　者：李星霞[1] 霍炎[1] 孙习鹏[1] 陈燕[1] 陆瑶华[1] 郭澄[1] LI Xingxia;HUO Yan;SUN Xipeng;CHEN Yan;LU Yaohua;GUO Cheng(Department of Pharmacy,Shanghai Jiao Tong University Affiliated Sixth People's Hospital,Shanghai 200233,China)

机构地区：[1]上海交通大学附属第六人民医院药剂科

出　　处：《药学实践杂志》2020年第1期77-80,共4页Journal of Pharmaceutical Practice

基　　金：上海交通大学医学院临床药学创新研究院青年项目(CXYJY2019QN003)

摘　　要：目的总结冠心病患者合并血小板减少的因素及相应处理措施,为临床治疗提供参考。方法通过对文献及病例报道进行分析和总结。结果冠心病患者合并血小板减少主要分两种情况,一种为冠心病抗栓治疗引起的血小板减少,另一种为冠心病患者合并的其他系统疾病或同时应用的非抗栓药物引起的血小板减少。不同原因引起的血小板减少,相应的处理措施及对冠心病患者的预后影响不同。结论冠心病合并血小板减少直接影响冠心病的治疗策略,早期监测、识别血小板减少症,快速判断病因并采取适当措施可有效改善冠心病患者的预后。Objective To summarize the factors and the corresponding treatments for patients with coronary heart disease(CHD)complicated by thrombocytopenia,and provide medical advises for clinical treatment.Methods Literatures and case reports were analyzed and summarized.Results Thrombocytopenia in patient with CHD could be mainly divided into two types,one group was induced by the antithrombotic therapies for CHD,and the other group was caused by some concurrent diseases or combined non-antithrombotic medications.There were different medical decisions and prognoses according to the causes in different groups.Conclusion The treatment strategies of CHD will be considered in the CHD patients with thrombocytopenia.Identifying thrombocytopenia by monitoring the platelet counts in early stage,finding out the causes quickly and providing proper treatments are the key for the prognosis of the patients.

关 键 词：冠心病 急性冠脉综合征 血小板减少症 抗栓治疗 抗血小板治疗 抗凝治疗 

分 类 号：R541.4[医药卫生—心血管疾病]